The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated. Under today’s EUA, the FDA is authorizing the emergency use of baricitinib, in combination with remdesivir, for the treatment of certain hospitalized patients with suspected or laboratory-confirmed COVID-19. The trial followed patients for 29 days and included 1,033 patients with moderate or severe COVID-19; 515 patients received baricitinib plus remdesivir, and 518 patients received placebo plus remdesivir. The median time to recovery from COVID-19 was seven days for baricitinib plus remdesivir and eight days for placebo plus remdesivir. The odds of clinical improvement at day 15 was higher in the baricitinib plus remdesivir group versus the placebo plus remdesivir group.
At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.